HomeCompareKERN vs PFE

KERN vs PFE: Dividend Comparison 2026

KERN yields 637.76% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 KERN wins by $423474.10M in total portfolio value
10 years
KERN
KERN
● Live price
637.76%
Share price
$0.31
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$423474.15M
Annual income
$323,645,811,110.73
Full KERN calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — KERN vs PFE

📍 KERN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodKERNPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, KERN + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
KERN pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

KERN
Annual income on $10K today (after 15% tax)
$54,209.18/yr
After 10yr DRIP, annual income (after tax)
$275,098,939,444.12/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, KERN beats the other by $275,098,917,124.22/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of KERN + PFE for your $10,000?

KERN: 50%PFE: 50%
100% PFE50/50100% KERN
Portfolio after 10yr
$211737.10M
Annual income
$161,822,918,684.72/yr
Blended yield
76.43%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

KERN
Analyst Ratings
2
Hold
Consensus: Hold
Altman Z
-0.1
Piotroski
2/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

KERN buys
0
PFE buys
0
No recent congressional trades found for KERN or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricKERNPFE
Forward yield637.76%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$423474.15M$49.6K
Annual income after 10y$323,645,811,110.73$26,258.71
Total dividends collected$415244.84M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldHold

Year-by-year: KERN vs PFE ($10,000, DRIP)

YearKERN PortfolioKERN Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$74,476$63,775.51$9,153$693.39+$65.3KKERN
2$523,587$443,898.47$8,593$849.25+$515.0KKERN
3$3,476,829$2,916,590.55$8,336$1,066.78+$3.47MKERN
4$21,820,514$18,100,306.58$8,437$1,384.80+$21.81MKERN
5$129,513,545$106,165,595.03$9,013$1,875.40+$129.50MKERN
6$727,491,274$588,911,781.24$10,306$2,680.72+$727.48MKERN
7$3,869,985,518$3,091,569,854.84$12,820$4,101.38+$3869.97MKERN
8$19,510,989,621$15,370,105,117.10$17,673$6,826.70+$19510.97MKERN
9$93,297,508,886$72,420,749,991.31$27,543$12,591.86+$93297.48MKERN
10$423,474,145,619$323,645,811,110.73$49,560$26,258.71+$423474.10MKERN

KERN vs PFE: Complete Analysis 2026

KERNStock

Akerna Corp. provides enterprise software solutions that enable regulatory compliance and inventory management in United States and Canada. The company offers MJ Platform for the cannabis, hemp, and CBD industry; and Leaf Data Systems, a government regulatory software. It also provides consulting services to cannabis industry; business intelligence, data analytics and other software related services; and Last Call Analytics, a tool for alcohol brands to analyze their retail sales analytics. In addition, the company operates seed-to-sale platform that offers tracking, reporting, and compliance tools to cannabis cultivators, processors, sellers, and clinics. Further, it provides cannabis cultivation management and compliance software; and cannabis tracking technology that offers seed-to-sale-to-self data. Akerna Corp. was founded in 2010 and is headquartered in Denver, Colorado.

Full KERN Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this KERN vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

KERN vs SCHDKERN vs JEPIKERN vs OKERN vs KOKERN vs MAINKERN vs JNJKERN vs MRKKERN vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.